Design of treatment trials in irritable bowel syndrome: Opioid agonists and atypical benzodiazepine antagonists

Neurogastroenterology and Motility

Volumn 20, Issue 10, 2008, Pages 1086-1093

  Mangel, A W ^a   Fehnel, S E ^a  

^a RTI HEALTH SOLUTIONS   (United States)

Author keywords

Adequate relief; Asimadoline; Dextofisopam; Irritable bowel syndrome; Kappa opioid agonists; Trial duration

Indexed keywords

ALOSETRON; ASIMADOLINE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; CILANSETRON; DEXTOFISOPAM; KAPPA OPIATE RECEPTOR AGONIST; LUBIPROSTONE; PLACEBO; TEGASEROD; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IRRITABLE COLON; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IRRITABLE BOWEL SYNDROME; QUALITY OF LIFE; RECEPTORS, GABA-A; RECEPTORS, OPIOID, KAPPA; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 51849135374     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2008.01198.x     Document Type: Review

References (43)

1. Lembo AJ. The clinical and economic burden of irritable bowel syndrome. Pract Gastroenterol, September Supplement, 2007 3 9.
2. Mayer EA. Irritable bowel syndrome. N Eng J Med 2008 358 : 1692 9.
3. Drossman DA. Rome III: The Functional Gastrointestinal Disorders. McLean, VA : Degnon Associates Inc., 2006.
4. Camilleri M, McKinzie S, Busciglio I et al. Prospective study of motor, sensory, psychologic and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008 6 : 772 81.
5. Watson ME, Lacey L, Kong S et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001 96 : 455 9.
6. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000 119 : 654 60.
7. Patel RP, Petitta A, Fogel R, Peterson E, Zarowitz BJ. The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol 2002 35 : 14 20.
8. Levy RL, Von Korff M, Whitehead WE et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001 96 : 3122 9.
9. Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female patients with alosetron, a 5HT3 receptor antagonist. Aliment Pharmacol Ther 1999 13 : 1149 59.
10. Camilleri M, Chet WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001 161 : 1733 40.
11. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial. Lancet 2000 355 : 1035 40.
12. Muller-Lissner SA, Fumagalli I, Bardhan KD et al. Tegaserod, a 5HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001 15 : 1655 66.
13. Novick L, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndromw with constipation. Aliment Pharmacol Ther 2002 16 : 1877 88.
14. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008 27 : 685 96.
15. Mangel AW. Study design issues in irritable bowel syndrome. Aliment Pharmacol Ther 2004 19 : 141 2.
16. Corazziari E, Bytzer P, Delvaux M et al. Consensus report: clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2003 18 : 569 80.
17. United States Package Insert Tegaserod. Available at: http://www.fda.gov/cder/drug/infopage/zelnorm/historical.htm. 2007 (accessed on 10 July 2008).
18. Leventer SM, Raudibaugh K, Frissora CL et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008 27 : 197 206.
19. Harding JP, Hamm LR, Ehsanullah RB et al. Use of a novel electronic data collection system in multicenter trials of irritable bowel syndrome. Aliment Pharmacol Ther 1997 11 : 1073 6.
20. Mangel AW, Northcutt AR. Review article: the safety and efficacy of alosetron, a 5HT3 receptor antagonist, in female irritable bowel syndrome patients. Aliment Pharmacol Ther 1999 13 : 77 82.
21. Labus JS, Naliboff BN, Fallon J et al. Sex differences in brain activity during aversive visceral stimulation and its expectation in patients with chronic abdominal pain: a network analysis. Neuroimage 2008 41 : 1032 43.
22. Mayer EA, Naliboff B, Lee O, Munakata J, Chang L. Review article: gender-related differences in functional gastrointestinal disorders. Aliment Pharmacol Ther 1999 13 (Suppl. 2 65 9.
23. Mangel AW. Personal view: adequate relief as a primary endpoint in irritable bowel syndrome. Aliment Pharmacol Ther 2006 23 : 879 81.
24. Mangel AW, Fehnel SE. Global endpoints in functional gastrointestinal disease. Aliment Pharmacol Ther 2005 22 : 1162 3.
25. Mangel AW, Hahn BA, Heath AT et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998 26 : 76 81.
26. Mangel AW, Bornstein JD, Hamm LR et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008 28 : 239 49.
27. Olden KW, Crowell MD. Cilansetron. Drugs Today (Barc) 2005 41 : 661 6.
28. Bijerk CJ, de Wit NJ, Muris JW, Jones RH, Knottnerus JA, Hoes AW. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol 2003 98 : 122 7.
29. Fehnel S, Johnston J, Kurtz C, Mangel A. Assessing global change and symptom severity in subjects with IBS: qualitative item testing. Am J Gastroenterol 2006 101 : S483.
30. Whitehead WE, Palsson OS, Levy RL. Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol 2006 101 : 1057 65.
31. Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 2007 5 : 534 40.
32. Mangel AW, Fehnel S. Adequate relief in IBS treatment trials: corrections to errors stated by Whitehead et al. Am J Gastroenterol 2006 101 : 2884 5.
33. US Department of Health and Human Services. Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims Draft Guidance. 2006. CDER2002193, docket no. 2006D-0044. 2008. Available from: http://www.fda.gov/cder/guidance/ 5460dft.pdf (accessed on 7 March 2007).
34. Andresen V, Camilleri M. Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs 2006 66 : 1073 88.
35. Camilleri M. Treating irritable bowel syndrome: overview, perspective and future therapies. Br J Pharmacol 2004 141 : 1237 48.
36. Camilleri M. Novel pharmacology: asimadoline, a κ-opioid agonist visceral sensation. Neurogastroenterol Motil 2008 20 : 971 9.
37. Burton MB, Gebhart GF. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998 285 : 707 15.
38. Kramer HJ, Uhl W, Ladstetter B, Backer A. Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man. J Clin Pharmacol 2000 50 : 227 35.
39. Delvaux M, Beck A, Jaco J, Bouzamondo H, Weber FT, Frexinos J. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004 20 : 237 46.
40. Delgado-Aros S, Chial HJ, Camilleri M et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol 2003 284 : G558 6.
41. Szarka LA, Camilleri M, Burton D et al. Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007 5 : 1268 75.
42. Leventer SM, Kucharik RF, Keogh JC et al. The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease. Am J Gastroenterol 2004 99 : S279.
43. Asimadoline Investigator's Brochure, Version 5.0. San Diego, CA : Tioga Pharmaceuticals. July 2006.